Cilfa Opposition, Dapagliflozin Empagliflozin Insulin, (Ar112015 A1)
No Annotations
Alert me when there are new annotations for this document
10 similar patent oppositions
-
CILFA opposition, trelagliptin, (AR109064A2)
Countries: Argentina Date: 2019
-
CILFA opposition, rosuvastatin, (P000100408)
Countries: Argentina Date: 2002
-
CILFA opposition, benzoilguanidinas (Markush), (P990106043)
Countries: Argentina Date: 2003
-
CILFA opposition, semaglutide, (AR114353A1)
Countries: Argentina Date: 2021
-
CILFA opposition, semaglutide, (AR112480A1)
Countries: Argentina Date: 2020
-
CILFA opposition, botulinum toxin A, (AR112121A1)
Countries: Argentina Date: 2019
-
CILFA opposition, cariprazine, (AR112137A1)
Countries: Argentina Date: 2019
-
CILFA opposition, buprenorphine, (AR110468A1)
Countries: Argentina Date: 2019
-
CILFA opposition, oprozomib, (AR110374A1)
Countries: Argentina Date: 2019
-
CILFA opposition, ibrutinib, (AR107391)
Countries: Argentina Date: 2019